Celldex Therapeutics Receives Fast-Track Designation For CDX-110, A Novel EGFRvIII Vaccine For Glioblastoma

January 08th, 2008 | Category: Cancer

Celldex Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celldex’s CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive structure of primary brain cancer

and carries a very poor prognosis with current therapy. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII that can be expressed by GBM.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Celldex Therapeutics Announces Orphan Drug Designation For CDX-110, A Novel EGFRvIII Vaccine For Glioblastoma Multiforme
  • Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
  • Dimericine(R) Receives FDA Fast Track Designation For Treatment Of Photosensitivity In XP Patients
  • Pharmion’s Oral Azacitidine Granted Fast Track Status For Myelodysplastic Syndromes
  • Seeking Funding For Cancer Vaccine Clinical Trial And Fast Track Commercialization

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.